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ABSTRACT 
Background and aims: Accurate estimates of the risk of hepatocellular carcinoma (HCC) in 
patients with cirrhosis are important for clinical decisions about HCC surveillance. We described 
HCC risk among outpatients with alcoholic cirrhosis and contrasted the risk of death from HCC 
with the risk of death from variceal bleeding or trauma. 
Methods: This was a nationwide, registry-based historical cohort study between 2006 and 2018. 
We included all Danish outpatients with a hospital diagnosis of alcoholic cirrhosis, except those 
with cancer, those with chronic viral hepatitis or autoimmune liver disease, and those older than 80 
years. We followed them through 2018 and described the cumulative risk of HCC and the 
cumulative risk of death from HCC, variceal bleeding, or trauma. 
Results: Of the 4553 included patients, 181 developed HCC and 2274 died. The cumulative risk of 
HCC was 0.9% (95% confidence interval [CI] 0.7 to 1.3) after 1 year, 3.6% (95% CI 3.0 to 4.2) 
after 5 years, and 6.0% (95% CI 5.1 to 7.0) after 10 years, or approximately 0.7% per year. Male 
gender, older age, and decompensated cirrhosis predicted a higher HCC risk. After 10 years, 6.9% 
of deaths in the cohort could be attributed to HCC, whereas 6.5% could be attributed to variceal 
bleeding, and 5.0% to trauma. 
Conclusions: In 2006–2018, Danish outpatients with alcoholic cirrhosis had an HCC risk of 0.7% 
per year, and they were nearly as likely to die from variceal bleeding or from trauma as from HCC. 
The implications are that many potentially harmful examinations are required for every HCC found 
through surveillance, so interventions targeting the prevention of other causes of death might be 
more cost-effective. 
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LAY SUMMARY 
We described the risk of hepatocellular carcinoma (HCC, the commonest form of liver cancer 
originating in the liver) in Danish outpatients with liver cirrhosis due to harmful alcohol 
consumption. Accurate data on that risk are important for patient counselling and decisions about 
screening for HCC. The risk was about 0.7% per year, which is lower than might be expected and 
suggests that many potentially harmful screening examinations are required for every HCC found 
through surveillance.  
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INTRODUCTION 
Alcoholic cirrhosis is a strong risk factor for hepatocellular carcinoma (HCC), and current United 
States and European guidelines recommend that patients with alcoholic cirrhosis be offered 
surveillance with an ultrasound examination every 6 months.1,2 The recommendation rests on 
observational studies and simulations that have identified a lower limit of 1.5% risk per year for 
cost-effective HCC surveillance.2 It is therefore unfortunate that studies of HCC risk continue to 
rely on the Kaplan-Meier method to describe HCC risk,3 despite the fact that it overestimates HCC 
risk substantially.4  
We have previously reported that the HCC risk was as low as 0.25% per year for Danish patients 
diagnosed with alcoholic cirrhosis in 1993–2005 and followed through 2009.5 In England it was 
even lower.6 HCC incidence has risen in the Danish general population since 2009,7 and it was a 
limitation of our former study that we did not consider cirrhosis severity; current HCC guidelines 
note that patients with the most severe cirrhosis (Child-Pugh class C) should not be offered 
surveillance.1,2 Given this background, we described the risk of HCC for patients with alcoholic 
cirrhosis who would be candidates for HCC surveillance. Our aim was to provide accurate up-to-
date information and context for informed decisions about HCC surveillance. 
PATIENTS AND METHODS 
Data sources 
We used data from nationwide Danish healthcare databases.8 The National Patient Registry includes 
data from inpatient and outpatient hospital contacts. For every contact, the treating physician 
specifies one primary diagnosis and up to twenty secondary diagnoses, coded according to the 
International Classification of Diseases, Tenth Revision (ICD-10). The National Patient Registry 
also contains records of all surgical procedures and imaging examinations.9 In addition, we used 
- 5 - 
 
data from the Cancer Registry,10 the Cause of Death Registry,11 the National Prescription 
Registry,12 and the Civil Registration System.13 Together, the registries provided individual-level 
data on diagnoses, surgical and endoscopic procedures, imaging examinations, prescription drug 
use, and dates and causes of death. The Cancer Registry records HCC stage according to the TNM 
staging system. According to Danish law, studies based entirely on data from registries require 
neither ethical approval nor patient consent. 
Study cohort 
We included all Danish citizens who 1) were followed as outpatients for alcoholic cirrhosis between 
1 January 2006 and 31 December 2017, 2) had received their first diagnosis of alcoholic cirrhosis 
exactly 6 months previously, 3) had not previously been diagnosed with any cancer, 4) had not within 
the previous 5 years received a diagnosis code for autoimmune liver disease or chronic viral hepatitis, 
and 5) were younger than 80 years. These patients were followed from the index date which was 6 
months after the date of their first diagnosis of alcoholic cirrhosis.  
We categorized the patients as compensated or decompensated. Patients categorized as having 
decompensated cirrhosis had one or more of the following before or on the index date: a diagnosis 
code for ascites, variceal bleeding, or hepatorenal syndrome; a procedure code for banding 
ligation/sclerotherapy of varices or for ascites puncture or drainage; or redemption of a prescription 
for spironolactone and furosemide, or for nonselective beta-blockers. The remaining patients were 
categorized as having compensated cirrhosis. All codes used in the study are shown in Supplementary 
Table 1. 
We identified all patients’ ultrasound, CT, or MRI examinations of the liver, upper abdomen, or 
entire abdomen. Finally, we extracted information about HCC treatments given with curative intent, 
defined as resection, ablation, or transplantation.  
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Study design 
Patients were followed from the index date until death or censoring on 31 December 2018. Other 
reasons for ending follow-up were defined by multistate models.4 Our first model had four states: 
‘Alive’ (literally, alive without HCC and without liver transplantation), ‘Liver transplant’, ‘HCC’, 
and ‘Dead’ (Supplementary Figure 1A). We used it to compute the risk of HCC (literally, risk of 
HCC before liver transplantation) in the full cohort. We defined HCC as a primary diagnosis code 
of HCC (C22.0) in the National Patient Registry or in the Cancer Registry. The earlier of the two 
registry records was the HCC diagnosis date.  
Our second model had five states because it divided the ‘Alive’ state in two by cirrhosis severity 
(compensated or decompensated) (Supplementary Figure 1B). Patients were moved from the 
compensated to the decompensated state on the earliest date they fulfilled the criteria for 
decompensated cirrhosis given above, and they could not re-compensate. Thus, the risk of HCC for 
patients with compensated cirrhosis was literally ‘the risk of developing HCC without having 
decompensated and before liver transplantation’, which is clinically relevant if HCC surveillance is 
restricted to patients with compensated cirrhosis. 
The multistate model shown in Supplementary Figure 2 was used in an analysis contrasting the risk 
of death from HCC with the risk of death from other causes. By our definition, all decedents who 
had been diagnosed with HCC died from HCC. For comparison, we identified deaths less than 30 
days after hospitalization for variceal bleeding or trauma as being attributable to those causes.  
We used the multistate model shown in Supplementary Figure 3 in an analysis describing the 
proportion of surviving patients who had had a liver imaging examination (ultrasound, CT, or MRI) 
within the previous 6 months. We had no data on the indication for the examination, but HCC 
surveillance was not recommended by Danish guidelines during the period of the study.14 Patients 
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were in the ‘Alive with recent liver imaging’ for 6 months after a liver imaging examination, and 
then they transited to ‘Alive without recent liver imaging’ and stayed there until their next 
examination. 
Statistical analysis 
Our goals were description and prediction, not causal inference.15 We aimed to describe the risk of 
HCC in the total cohort and within strata defined by key characteristics: gender, age, cirrhosis 
severity, and calendar year. In our analyses of multistate disease models, we used the cumulative 
incidence function to compute the risk of making a specific transition from one disease state to the 
next. We used the Aalen-Johansen method to compute the probability of being in a specific state at 
a specific time during the follow-up.4,16 The Kaplan-Meier estimator was used in analyses of all-
cause mortality. We computed HCC incidence rates and rates of liver imaging examinations 
(separately for ultrasound and CT/MRI) for every calendar year of the study period to examine time 
trends. In this analysis, patients could have multiple imaging examinations during the follow-up, 
but examinations conducted on the same day counted as one examination. We computed the risk of 
HCC per year as the cumulative risk of HCC after x years divided by x. This is not a formal 
statistical procedure, but we used it to facilitate comparison with international guidelines.1,2 
We estimated predicted probabilities of HCC for patients of varying gender, age, and cirrhosis 
severity. These predictions were based on a Fine & Gray regression model including gender, current 
age, current cirrhosis severity, and current calendar year as predictors of the subdistribution hazard 
ratio for HCC. Age, cirrhosis severity, and calendar year were time-dependent variables, and age 
and calendar year were included as linear variables. Predictions were subsequently computed as 
described by Therneau.17  
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Sensitivity analysis 
We expanded our definition of HCC to explore how our estimates of HCC risk could have been 
affected by the possibility that some HCCs had been overlooked or diagnosed but miscoded. We 
added the following: 1) HCCs coded as a secondary diagnosis in the National Patient Registry; 2) 
cancers with a diagnosis code of C22.9 (unspecified primary liver cancer) in the Cancer Registry or 
as a primary or secondary diagnosis in the National Patient Registry; and 3) HCCs or unspecified 
primary liver cancers recorded only in the Cause of Death Registry. In this last case we used the 
date of death as the date of HCC diagnosis. 
We used multistate modeling to explore the extent to which we underestimated HCC risk by 
assuming that an HCC did not exist before it was diagnosed. With this approach, the data are 
thought to represent snapshots of an underlying disease process that progresses through clinically 
defined states,18 here from ‘alive, no HCC’ to ‘death’ with the possibility of transitioning through 
an intermediate ‘alive with HCC’ state. The snapshots were the dates of imaging examinations, 
HCC diagnosis, and death. We assumed the following: HCCs might have developed before they 
were diagnosed; patients who died or were censored might have developed an undiagnosed HCC; 
dates of death were exact; patients might have HCC on the date of a CT or MRI examination, or on 
the date of an ultrasound examination that was followed within 14 days by a CT or MRI 
examination; and patients did not have HCC on the date of other ultrasound examinations. This 
approach must yield higher estimates of HCC risk than our primary analysis because it allowed for 
undiagnosed HCCs. We modeled the effects of gender, age, cirrhosis severity, and calendar year on 
the transition rates using the ‘msm’ package for R,18 and we used them to compute predicted 
probabilities of HCC development for various patient characteristics. 
We conducted our primary analysis restricting it to patients who at inclusion were followed at either 
of Denmark’s two departments specialized in hepatology (Copenhagen, department code 130115; 
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Aarhus, department codes 700336 and 662036), and who had also received their first diagnosis of 
alcoholic cirrhosis at the same departments. The purpose of this analysis was to examine whether 
patients followed by specialists were more likely to be diagnosed with HCC. 
Finally, we repeated our primary analysis excluding variceal bleeding as a criterion defining 
decompensation. Patients with variceal bleeding alone have a lower mortality than patients with 
ascites or hepatic encephalopathy,19 so it may be more appropriate to consider them as being part of 
the population who should be under surveillance Specifically, for this purpose, we removed variceal 
bleeding, banding ligation/sclerotherapy, and nonselective beta-blockers from the criteria defining 
decompensation. 
RESULTS 
We included 4553 patients. Their median age was 59.3 years at inclusion (interquartile range 52.5–
65.2), 67% were men, and 22% had compensated cirrhosis (Table 1). Men below the age of 60 
years constituted 36% percent of the cohort. During 18,384 person-years of follow-up, 2274 
patients died (mortality rate = 124 per 1000 person-years). All-cause mortality was 12% after 1 
year, 46% after 5 years, and 71% after 10 years. It was higher for those who were decompensated as 
opposed to compensated at inclusion: 13% vs. 9% after 1 year, 48% vs. 39% after 5 years, and 74% 
vs. 62% after 10 years (Supplementary Figure 4). 
During the follow-up 41 patients received a liver transplant, and 181 were diagnosed with HCC. Of 
those 181 patients, 19 had compensated cirrhosis and 162 had decompensated cirrhosis, including 
20 patients who presented with compensated cirrhosis but decompensated during follow-up and 
were diagnosed with HCC after that. The cumulative risk of HCC was 0.9% (95% confidence 
interval [CI] 0.7 to 1.3) after 1 year, 3.6% (95% CI 3.0 to 4.2) after 5 years, and 6.0% (95% CI 5.1 
to 7.0) after 10 years. Thus, the average risk per year was around 0.7%, slightly higher in the first 5 
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years, slightly lower thereafter (Figure 1, left). HCC risk was much higher for men than for women 
(5-year risk = 4.6% [95% CI 3.8 to 5.5] vs. 1.4% [95% CI 0.9 to 2.2], Figure 1, left), and lower for 
patients with compensated cirrhosis (5-year risk = 2.2% [95% CI 1.3 to 3.4] vs. 3.5% [95% CI 2.8 
to 4.1], Figure 1, right). The 3-year outcomes of the 980 patients with compensated cirrhosis were: 
1.4% developed HCC, 0.1% was transplanted, 33.4% decompensated, 12.9% died without HCC, 
and 52.2% did not experience any event. 
In the full cohort of 4553 patients, deaths from HCC accounted for 5.5% of all deaths after 5 years, 
and for 6.9% of all deaths after 10 years. Deaths after variceal bleeding (6.5% of deaths after 10 
years) or after trauma (5.0%) were nearly as frequent (Figure 2). Among men, the proportion of all 
deaths attributable to HCC was 8.6% after 10 years, while among women this proportion was 3.0%. 
The registered causes of death are presented in Supplementary Table 2. 
Of the 19 patients with compensated cirrhosis who developed HCC, only 5 (26%) were treated with 
curative intent, all with tumor ablation. Of those 5 patients, 3 had T1 or T2 HCC, and 2 did not have 
the TNM stage recorded. Of the other 14 patients, 2 had T4 HCC and extrahepatic spread, 2 had T3 
HCC, 5 had T1 or T2 HCC, and 5 did not have the TNM stage recorded. Supplementary Figure 5 
shows the imaging examinations done from the beginning of follow-up to the date of HCC 
diagnosis.  
The proportion of surviving patients with a liver imaging examination within the previous 6 months 
was 63% at the beginning of follow-up, and then rapidly declined to 24% after 1 year to decline 
more slowly to 20% after 5 years and 16% after 10 years (Supplementary Figure 6). It increased 
during the study period, from less than 10% in 2007 to 25% by the end of 2018 (Supplementary 
Figure 7). Of the 402 patients who had their first variceal bleeding during the follow-up, 73% had a 
liver imaging examination less than 6 months before or after that bleeding episode. Of the 2137 
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patients who died without having been diagnosed with HCC, 64% had had a liver imaging 
examination less than 6 months before death. 
Time-trends in HCC incidence 
The incidence rate of HCC was 10.0 per 1000 person-years (95% CI 8.6 to 11.5), with an increasing 
trend during the 2008–2013 period followed by stabilization. The rates of ultrasound and CT/MRI 
examinations of the liver rose continuously, reaching a combined rate of nearly 1000 per 1000 
person-years in 2018, i.e., 1 examination per patient per year (Figure 3). 
Predicted HCC risks 
Male gender (subdistribution hazard ratio [sHR] = 3.08, 95% CI 2.02 to 4.70), older age (sHR = 
1.06 per year, 95% CI 1.04 to 1.08), and later calendar year (sHR = 1.06 per year, 95% CI 1.01 to 
1.11) were risk factors for HCC. Decompensated cirrhosis also predicted a higher risk of HCC, but 
this association did not reach statistical significance (sHR = 1.51, 95% CI 0.94 to 2.43). For 
women, all predicted risks were below 1% per year. Only men aged 70 years or older had a 
predicted HCC risk reaching 1.5% per year (Table 2). 
Sensitivity analysis 
Via our expanded definition of HCC we identified 33 possible HCCs, bringing the total to 214. 
With this expanded HCC definition, the cumulative risk of HCC was 1.2% (95% CI 0.9 to 1.6) after 
1 year, 4.2% (95% CI 3.6 to 4.9) after 5 years, and 7.0% (95% CI 5.9 to 8.2) after 10 years. When 
instead we used the snapshot approach allowing for undiagnosed HCCs, we found that the 
cumulative risk of HCC was 1.0% (95% CI 0.9 to 1.3) after 1 year, 4.3% (95% CI 3.5 to 5.1) after 5 
years, and 6.7% (95% CI 5.6 to 8.1) after 10 years. With this approach, younger men (60 years or 
older) had a predicted risk of HCC approaching 1.5% per year, but still no women did 
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(Supplementary Table 3). Restricting the analysis to patients followed by hepatologists, the 5-year 
risk of HCC was 4.6% (95% CI 3.1 to 6.5) vs. 3.6% (95% CI 3.0 to 4.2) in the primary analysis, and 
the mortality rate was 133 per 1000 person-years vs. 124 per 1000 person-years in the primary 
analysis. When we excluded variceal bleeding from the definition of decompensation, the 5-year 
risk of HCC among those with compensated alcoholic cirrhosis rose from 2.2% (95% CI 1.3 to 3.4) 
to 3.2% (95% CI 2.3 to 4.3), and the predicted 5-year risk of HCC for a 60-year old man with 
compensated alcoholic cirrhosis in the year 2018 rose from 3.7% (95% CI 1.8 to 5.5) to 5.4% (95% 
CI 3.4 to 7.4). 
DISCUSSION 
We described HCC risk and found that Danish outpatients with alcoholic cirrhosis had a low risk of 
HCC (0.7% per year). We predicted HCC risks for patients of varying gender, age, and cirrhosis 
severity and found that only men aged 70 years or older can be expected to have an HCC risk of 
1.5% per year or higher. Sensitivity analyses including possible or undiagnosed HCCs yielded HCC 
risks around 0.9% per year and indicated that also men aged 60 years could potentially have an 
HCC risk of 1.5% per year. After 10 years, 6.9% of deaths in this population could be attributed to 
HCC, 6.5% to variceal bleeding, and 5.0% to trauma. 
Current recommendations about HCC surveillance rely on estimates of HCC risk. We may have 
underestimated the true HCC risk if our patients did in fact not have cirrhosis, or if we failed to 
identify HCCs. The reported positive predictive value for a registry diagnosis code for alcoholic 
cirrhosis is around 80%,20-22 but it was likely higher in this study because we included only patients 
who were given the diagnosis code twice. Moreover, most of our patients had additional codes for 
diagnoses, procedures, or medical treatments that corroborated the cirrhosis diagnosis. It remains 
possible that some patients did in fact have alcoholic hepatitis without cirrhosis, and therefore a 
- 13 - 
 
lower risk of HCC, but we are confident that the vast majority of our patients in fact had alcoholic 
cirrhosis. The completeness of the Cancer Registry ensured that all diagnosed HCCs were captured, 
and we supplemented Cancer Registry data with primary diagnosis codes from the National Patient 
Registry. Adding possible or undiagnosed HCCs, or restricting the analysis to patients followed by 
specialists, raised the estimates of HCC risk, but did not change the conclusion that only men, and 
only the older of them, have an HCC risk above 1.5% per year.   
We categorized patients as compensated or decompensated and found that 79% had decompensated 
before study inclusion. This high proportion is similar to what we found in our 2010 study based on 
data from patients’ medical charts (76%),19 indicating that our definition was valid. Nonetheless, it 
is a limitation of our study that we could not categorize patients by Child-Pugh class, which is the 
categorization used in current HCC guidelines. It is an additional limitation that we could not 
determine whether patients were fit to receive HCC surveillance although in truth this is not easy to 
determine without individualized assessment. 
Our patients with compensated cirrhosis had nearly as high all-cause mortality as those with 
decompensated cirrhosis. A recent regional study from Sweden found the same, an all-cause 
mortality hazard ratio for patients presenting with decompensated vs. compensated cirrhosis of only 
1.13 (95% CI 0.95 to 1.35).23 Probably, many patients who present with compensated alcoholic 
cirrhosis decompensate early despite the clinical care they receive. In our Danish study using data 
from medical records,19 we found virtually the same mortality hazard ratio, 1.16 (95% CI 0.88 to 
1.52), and within 1 year 22% of compensated patients decompensated while 10% died without 
having decompensated. At 5 years the numbers were 49% and 22%, respectively. Such a poor 
prognosis resonates with what we find here for patients with compensated alcoholic cirrhosis: 
within 3 years 33.4% of patients decompensated, and 12.9% died without HCC. Moreover, only 5 
of 19 patients with compensated cirrhosis could be offered curative treatment for HCC. Why so 
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few? Although only 12 of the 19 patients had data on TNM stage, we could show that some had too 
advanced HCC (4 patients had T3 or T4 HCC), while others must have had too advanced cirrhosis 
or comorbidities (5 patients had T1 or T2 HCC yet were not treated with curative intent). These 
observations indicate that even our patients with compensated cirrhosis had severely reduced liver 
function.  
The HCC risks presented here are lower than those reported by Ganne-Carrie et al. for a French 
cohort with Child-Pugh class A alcoholic cirrhosis.24 In the French study, the HCC incidence rate 
was 29 per 1000 person-years and the HCC risk was approximately 2.6% per year. A key difference 
is that we included all Danish patients meeting our inclusion criteria, whereas patients in the Ganne-
Carrie study were recruited from 28 specialist centers. This raises the question of selection bias. 
First, the French patients included in the study could have had a higher HCC risk than French 
patients who met the same inclusion criteria but were not included. Second, 23.5% of the patients in 
the French study were lost to follow-up. Assumptions about these patients’ mortality and HCC risk 
have a strong effect on estimates of HCC risk: If in fact they died soon after dropping out, HCC risk 
would have been considerably lower than what was reported. Estimates of HCC risk can be severely 
upward-biased if deaths without HCC are not identified, as in the study from France, or if they are 
not accounted for in the analysis, as in the study from Spain by Mancebo et al. or the study from the 
United States by Ioannou et al.3,4,25 The above-mentioned Swedish study did not have any of those 
shortcomings.26 In that cohort the incidence rate of HCC was 15 per 1000 person-years (Harald 
Anderson, personal communication), which is higher than the 10 per 1000 person-years in our 
cohort, but random variation might explain this difference in HCC incidence rate between Sweden 
and Denmark.  
It is conceivable that there is true geographic variation in HCC incidence, attributable to differences 
in the prevalence of HCC risk factors. The PNPLA3 gene is the strongest known genetic risk factor 
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for HCC development, but there are no data on geographic differences in its prevalence in patients 
with alcoholic cirrhosis. However, a recent review indicated that the prevalence of the risk variant is 
very similar throughout Europe and in the United States.27 Environmental risk factors for HCC, like 
aflatoxin exposure, also cannot explain the differences between low-risk countries like Denmark, 
Sweden, and England and high-risk countries like France, Spain, and the United States.28 
Differences in the prevalence of comorbidity, primarily diabetes,3 of chemopreventive drugs like 
statins and metformin, and of coffee consumption or tobacco smoking may have contributed.29  
Our study showed that HCC incidence increased in parallel with liver imaging examinations until 
around 2013. We speculate that some HCCs were overlooked before that, but identification is now 
more complete, as indicated by the flattening of the HCC incidence rate curve despite the increasing 
use of liver imaging examinations. The structural change underlying these trends was the 
introduction of a Cancer Patient Pathway for primary liver cancer in 2009.30,31 That pathway allows 
general practitioners to refer patients with cirrhosis and a focal liver lesion to urgent workup led by 
HCC specialists. Pathways for other cancers have been introduced, and although they do not affect 
the true incidence of HCC, they increase the number of imaging examinations that are being done, 
and it probably means that fewer HCCs are overlooked. We showed that the proportion of patients 
under surveillance increased during the study period, but in our clinical experience imaging 
examinations are primarily done in patients with perceived high risk of HCC. We acknowledge that 
a substantial proportion of our cohort did not have imaging examinations during the follow-up, and 
that it remains possible that we underestimated the incidence of HCC. Autopsy is very rarely 
conducted, and the incomplete examination of patients remains a limitation of our study. 
We see four candidate explanations to the relatively low HCC risk in our population: First, it could 
be explained by the high mortality among patients with compensated alcoholic cirrhosis, which 
itself might be a Northern European characteristic. Second, it could be explained by our failure to 
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diagnose HCCs. However, we believe that our findings are a reasonably pragmatic reflection of the 
natural history of HCC development and clinical presentation in alcoholic cirrhosis. With complete 
ascertainment of HCCs we would inevitably have HCC overdiagnosis, i.e., we would have 
diagnosed HCCs that would not have had any impact on the patient’s quality or quantity of life had 
it not been diagnosed.32 Third, it could be explained by true geographic variation in HCC incidence. 
Fourth, it could be an artifact, the result of differences in data availability and analysis. We 
speculate that this fourth possibility explains the majority of the apparent geographical variation. 
Does HCC surveillance provide value for money? Assume that for 3 years we offer HCC 
surveillance to 1000 patients with compensated alcoholic cirrhosis. Based on our findings, 14 will 
be diagnosed with HCC, 1 will be transplanted, 334 will decompensate and thus leave the 
surveillance program, and 129 will die without HCC. Of the 14 patients with HCC, 26% would 
receive curative treatment under our current standard of care, so 74% of patients with HCC benefit 
from surveillance, assuming optimistically that ultrasound screening has 100% sensitivity for small 
HCCs. More realistically, the sensitivity is 47%,33 so we estimate that 14*0.74*0.47 = 5 patients 
benefit per 1000 offered HCC surveillance for 3 years. The base costs are 522 patients * 2 
examinations per patient per year * 3 years + 478 patients * 2 examinations per patient per year * 
1.5 years = 4566 ultrasound examinations, assuming that those who experience an event do so 
halfway through the surveillance period. Atiq et al. followed 523 cirrhosis patients who were 
offered HCC surveillance for 3 years and received at least one ultrasound examination; 119 (23%) 
of them experienced harm, primarily due to diagnostic CT and MRI scans for false-positive or 
indeterminate screening results.34 We may consequently assume that at least 230 of our hypothetical 
1000-patient cohort will experience harm, thus adding costs and potentially reducing quality of life. 
An analysis such as this is by no means definitive, but it is consistent with a recent review which 
estimated that 400 patients with cirrhosis must be surveilled to prevent one death,35 and it provides 
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an argument for restricting HCC surveillance to high-risk populations.33 We found that male 
gender, older age, and severity of portal hypertension predicted a higher risk of HCC development, 
and that is consistent with two recent North American studies.3,36 Now further studies are needed to 
determine the efficacy and cost-effectiveness of offering HCC surveillance to older men with 
decompensated alcoholic cirrhosis, who also have a high mortality from non-HCC causes.  
We speculate that other interventions could provide better value for money than HCC surveillance. 
One possibility is to provide wider access to early insertion of a transjugular intrahepatic 
portosystemic shunt to manage acute variceal bleeding.37,38 Another possibility is to improve the 
treatment of alcohol use disorders. It could potentially prevent both trauma and variceal bleeding, 
and improve quality of life, too, but we recognize that the evidence in this field is limited.39  
In conclusion, we found that HCC plays a relatively small role in the clinical course of alcoholic 
cirrhosis, particularly among female patients. The resources spent on HCC surveillance might be 
better spent on other interventions to improve quantity and quality of life.  
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Table 1. Characteristics of the study population. 
 Compensated Decompensated All 
Number of patients 980 3573 4553 
Gender    
   Men 667 (68%) 2405 (67%) 3072 (67%) 
   Women 313 (32%) 1168 (33%) 1481 (33%) 
Age    
   <50 182 (19%) 603 (17%) 785 (17%) 
   50–59 350 (36%) 1312 (37%) 1662 (37%) 
   60–69 355 (36%) 1300 (36%) 1655 (36%) 
   70–79 93 (9%) 358 (10%) 451 (10%) 
   Median age (IQR) 59.2 (52.1 – 65.5) 59.3 (52.5 – 65.1) 59.2 (52.4 – 65.0) 
Outcomes (first event only)    
   Decompensation 390 - 390 
   HCC* 19 142 161 
   Liver transplantation† 1 29 30 
   Death‡ 170 1765 1935 
   No event 400 1637 2037 
Follow-up time, total (to first event) 3024 years 14,039 years 17,063 years 
* 20 patients had compensated cirrhosis initially and were diagnosed with HCC after having 
decompensated. 
† 7 patients had compensated cirrhosis initially and underwent liver transplantation after having 
decompensated. 
‡ 339 patients died after having experienced one or more events. 
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Table 2. Predicted risks of HCC. All are predictions for 2018, the last year of our study period 
and the most relevant year for future decisions about HCC surveillance. Predictions for earlier years 
are lower. 
Cirrhosis severity Gender Age 1-year risk 5-year risk 10-year risk 
Compensated Woman 50 0.2% (0.1 – 0.3) 0.7% (0.2 – 1.1) 1.0% (0.3 – 1.7) 
Compensated Woman 60 0.3% (0.1 – 0.6) 1.2% (0.5 – 1.9) 1.9% (0.7 – 3.0) 
Compensated Woman 70 0.6% (0.2 – 1.1) 2.2% (0.9 – 3.5) 3.4% (1.4 – 5.4) 
Compensated Man 50 0.6% (0.2 – 0.9) 2.0% (0.9 – 3.2) 3.1% (1.3 – 4.9) 
Compensated Man 60 1.1% (0.5 – 1.7) 3.7% (1.8 – 5.5) 5.7% (2.8 – 8.4) 
Compensated Man 70 1.9% (0.9 – 3.0) 6.7% (3.4 – 9.8) 10.2% (5.3 – 14.8) 
Decompensated Woman 50 0.3% (0.1 – 0.5) 1.0% (0.5 – 1.5) 1.5% (0.7 – 2.3) 
Decompensated Woman 60 0.5% (0.2 – 0.8) 1.8% (1.0 – 2.6) 2.8% (1.6 – 4.0) 
Decompensated Woman 70 1.0% (0.5 – 1.5) 3.3% (1.8 – 4.8) 5.1% (2.9 – 7.3) 
Decompensated Man 50 0.9% (0.5 – 1.3) 3.0% (1.9 – 4.2) 4.7% (2.9 – 6.4) 
Decompensated Man 60 1.6% (1.0 – 2.2) 5.5% (4.0 – 7.1) 8.4% (6.2 – 10.6) 
Decompensated Man 70 2.9% (1.8 – 4.0) 9.9% (7.2 – 12.5) 14.9% (11.4 – 18.4) 
 
  




Fig. 1. Cumulative risk of HCC in the cohort of 4553 outpatients with alcoholic cirrhosis. The 
risk is shown by gender (left) and by compensated or decompensated cirrhosis at inclusion (right). 
For patients with compensated cirrhosis, the risk of HCC presented in the figure is literally ‘the risk 
of developing HCC without having decompensated and before liver transplantation’. 
Fig. 2. Cumulative mortality in the cohort of 4553 outpatients with alcoholic cirrhosis. The 
color indicates cause of death. 
Fig. 3. Incidence rates of HCC (red) and of liver imaging (blue and green, right-side y axis). 
The actual annual rates are shown in the thin, brighter lines. The thick, darker lines are lowess 
smoothing plots to facilitate the visual interpretation of time trends. 
